A novel -32 (C-A) mutant identified in amplified genomic DNA of a Chinese beta-thalassemic patient.

Por Lin, L I, Lin, K S, Lin, K H, Cheng, T Y
Publicado em 1992

The spectrum of beta-thalassemia mutations in Taiwan: identification of a novel frameshift mutation.

Por Lin, L I, Lin, K S, Lin, K H, Chang, H C
Publicado em 1991

Reply to ‘Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis’

Por Hou, H-A, Lin, L-I, Chen, C-Y, Tien, H-F
Publicado em 2009

Cell type-specific protein-DNA interactions in the human zeta-globin upstream promoter region: displacement of Sp1 by the erythroid cell-specific factor NF-E1.

Por Yu, C Y, Chen, J, Lin, L I, Tam, M, Shen, C K
Publicado em 1990

Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia

Por Lee, C-Y, Tien, H-F, Hu, C-Y, Chou, W-C, Lin, L-I
Publicado em 2007

Overexpression of SOX4 correlates with poor prognosis of acute myeloid leukemia and is leukemogenic in zebrafish

Por Lu, J-W, Hsieh, M-S, Hou, H-A, Chen, C-Y, Tien, H-F, Lin, L-I
Publicado no Blood Cancer J (2017)

Clinico-biological significance of suppressor of cytokine signaling 1 expression in acute myeloid leukemia

Por Hou, H-A, Lu, J-W, Lin, T-Y, Tsai, C-H, Chou, W-C, Lin, C-C, Kuo, Y-Y, Liu, C-Y, Tseng, M-H, Chiang, Y-C, Peng, Y-L, Tang, J-L, Gong, Z, Lin, L-I, Tien, H-F
Publicado no Blood Cancer J (2017)

TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution

Por Hou, H-A, Chou, W-C, Kuo, Y-Y, Liu, C-Y, Lin, L-I, Tseng, M-H, Chiang, Y-C, Liu, M-C, Liu, C-W, Tang, J-L, Yao, M, Li, C-C, Huang, S-Y, Ko, B-S, Hsu, S-C, Chen, C-Y, Lin, C-T, Wu, S-J, Tsay, W, Chen, Y-C, Tien, H-F
Publicado no Blood Cancer J (2015)